New CAR-T therapy aims to control aggressive blood cancer
NCT ID NCT07473167
First seen Mar 16, 2026 · Last updated May 01, 2026 · Updated 9 times
Summary
This study tests a new treatment called TC011, which uses a patient's own immune cells (CAR-T cells) to fight a type of blood cancer called large B-cell lymphoma. The trial is for adults whose cancer has come back or not responded to at least two prior treatments. The goal is to see if TC011 is safe and can shrink or control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, Seoul, 03080, South Korea
Contact
Conditions
Explore the condition pages connected to this study.